# The Miami "EMPIRE" Trial - Eradication of Metastatic Pancreatic Cancer With Immuno-Radiation

> **NCT06843551** · PHASE2 · RECRUITING · sponsor: **Benjamin Spieler** · enrollment: 20 (estimated)

## Conditions studied

- Metastatic Pancreatic Ductal Adenocarcinoma
- Metastatic Pancreatic Cancer

## Interventions

- **RADIATION:** Stereotactic Body Radiation Therapy
- **DRUG:** Botensilimab
- **DRUG:** Balstilimab

## Key facts

- **NCT ID:** NCT06843551
- **Lead sponsor:** Benjamin Spieler
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-18
- **Primary completion:** 2030-08-01
- **Final completion:** 2030-08-01
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-08-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06843551

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06843551, "The Miami "EMPIRE" Trial - Eradication of Metastatic Pancreatic Cancer With Immuno-Radiation". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06843551. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*